Preventive Effects of Prasugrel on Cerebrovascular Events Following Percutaneous Coronary Intervention
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Dual antiplatelet drug administration is recommended after percutaneous coronary intervention (PCI) stent placement. Although prasugrel, a newer P2Y12 inhibitor, reportedly suppresses cardiovascular events more effectively than the traditional agent clopidogrel, its preventive effects on cerebrovascular disorders remain a topic of ongoing debate. This study aimed to examine the cerebrovascular efficacy and safety of post-PCI prasugrel and clopidogrel using extensive real-world data in Japan. METHODS: Using the CLIDAS (Clinical Deep Data Accumulation System) database, 7412 post-PCI patients who received dual antiplatelet therapy between April 2013 and March 2019 were identified. The primary end point was defined as the incidence of any stroke, while secondary end points included individual ischemic and hemorrhagic cerebrovascular events. The incidence of cerebrovascular events was compared between the prasugrel (2.5–3.75 mg daily; n=2219) and clopidogrel (75 mg daily; n=5193) groups using propensity-score inverse probability of treatment weighting and Fine and Gray models to account for competing risks. RESULTS: Within 1 year after PCI, the prasugrel group had a significantly lower incidence of cerebrovascular events (subdistribution hazard ratio, 0.46 [95% CI, 0.24–0.91]; P =0.027) than the clopidogrel group. The subgroup analyses did not show significant differences in the incidence of ischemic (subdistribution hazard ratio, 0.54 [95% CI, 0.25–1.14]; P =0.11) and hemorrhagic cerebrovascular events (subdistribution hazard ratio, 0.30 [95% CI, 0.084–1.10]; P =0.070) between the use of prasugrel and clopidogrel. One-year health care costs between patients treated with prasugrel and those treated with clopidogrel showed no significant differences. CONCLUSIONS: Our data suggest that post-PCI prasugrel use was associated with lower cerebrovascular events compared with the use of clopidogrel in combination with aspirin. Further research is necessary to substantiate the potential of prasugrel in lowering cerebrovascular risks after post-PCI while upholding a satisfactory safety profile.
Source: Stroke
Authors: Hisaki Makimoto, Yusuke Sasabuchi, Tomoyuki Kabutoya, Takahide Kohro, Hayato Yamana, Yusuke Oba, Yasushi Imai, Kazuomi Kario, Hisahiko Sato, Arihiro Kiyosue, Yoshiko Mizuno, Kotaro Nochioka, Masaharu Nakayama, Takamasa Iwai, Yoshihiro Miyamoto, Masanobu Ishii, Taishi Nakamura, Kenichi Tsujita, Naoyuki Akashi, Hideo Fujita, Hideo Yasunaga, Tetsuya Matoba, Ryozo Nagai, Kenichi Aizawa, Takayuki Fujiwara, Mitsuhiro Fukata, Kazutoshi Hirose, Masamichi Ito, Hiroshi Kadowaki, Shunsuke Katsuki, Yoshimasa Kawazoe, Risa Kishikawa, Takeshi Kitai, Satoshi Kodera, Shun Minatsuki, Koki Nakanishi, Yasuhiro Nakano, Naoki Nakashima, Teruo Noguchi, Kenichi Sakakura, Masataka Sato, Shinnosuke Sawano, Hayato Shimizu, Hiroki Shinohara, Katsura Soma, Yoko Sumita, Jun Takahashi, Norihiko Takeda, Kensuke Tsushima, Yoshinori Yamanouchi, Takanori Yamashita, Atsushi Yao, Satoshi Yasuda
Institutions: Jichi Medical University, Institute of Medical Science, The University of Tokyo, The University of Tokyo, University of Tokyo Hospital, Development Bank of Japan, Tohoku University, National Cerebral and Cardiovascular Center, Open Innovation Center, National Cerebral and Cardiovascular Center, National Cerebral and Cardiovascular Center Hospital, Kumamoto University, Jichi Medical University Saitama Medical Center, Kyushu University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4410696536
